Literature DB >> 20005318

Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Lauriane E Quenee1, Bryan J Berube, Joshua Segal, Derek Elli, Nancy A Ciletti, Deborah Anderson, Olaf Schneewind.   

Abstract

LcrV, a protein that resides at the tip of the type III secretion needles of Yersinia pestis, is the single most important plague protective antigen. Earlier work reported monoclonal antibody MAb 7.3, which binds a conformational epitope of LcrV and protects experimental animals against lethal plague challenge. By screening monoclonal antibodies directed against LcrV for their ability to protect immunized mice against bubonic plague challenge, we examined here the possibility of additional protective epitopes. MAb BA5 protected animals against plague, neutralized the Y. pestis type III secretion pathway and promoted opsonophagocytic clearance of bacteria in blood. LcrV residues 196-225 were necessary and sufficient for MAb BA5 binding. Compared to full-length LcrV, a variant lacking its residues 196-225 retained the ability of eliciting plague protection. These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005318      PMCID: PMC2822060          DOI: 10.1016/j.vaccine.2009.11.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

Authors:  Kristin L DeBord; Deborah M Anderson; Melanie M Marketon; Katie A Overheim; R William DePaolo; Nancy A Ciletti; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 2.  The type III secretion system tip complex and translocon.

Authors:  C A Mueller; P Broz; G R Cornelis
Journal:  Mol Microbiol       Date:  2008-04-08       Impact factor: 3.501

3.  LcrV plague vaccine with altered immunomodulatory properties.

Authors:  Katie A Overheim; R William Depaolo; Kristin L Debord; Elizabeth M Morrin; Debra M Anderson; Nathaniel M Green; Robert R Brubaker; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

Authors:  J Bashaw; S Norris; S Weeks; S Trevino; J J Adamovicz; S Welkos
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

Review 5.  The virulence plasmid of Yersinia, an antihost genome.

Authors:  G R Cornelis; A Boland; A P Boyd; C Geuijen; M Iriarte; C Neyt; M P Sory; I Stainier
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

6.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

7.  YopB and YopD constitute a novel class of Yersinia Yop proteins.

Authors:  S Håkansson; T Bergman; J C Vanooteghem; G Cornelis; H Wolf-Watz
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

8.  Function and molecular architecture of the Yersinia injectisome tip complex.

Authors:  Petr Broz; Catherine A Mueller; Shirley A Müller; Ansgar Philippsen; Isabel Sorg; Andreas Engel; Guy R Cornelis
Journal:  Mol Microbiol       Date:  2007-09       Impact factor: 3.501

Review 9.  Current challenges in the development of vaccines for pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

10.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  22 in total

Review 1.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

2.  Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.

Authors:  Juliette K Tinker; Chadwick T Davis; Britni M Arlian
Journal:  Protein Expr Purif       Date:  2010-05-11       Impact factor: 1.650

3.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

4.  A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.

Authors:  Paul Warrener; Reena Varkey; Jessica C Bonnell; Antonio DiGiandomenico; Maria Camara; Kimberly Cook; Li Peng; Jingying Zha; Partha Chowdury; Bret Sellman; C Kendall Stover
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

5.  Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Authors:  Bryan J Berube; Katherine R Murphy; Matthew C Torhan; Nicholas O Bowlin; John D Williams; Terry L Bowlin; Donald T Moir; Alan R Hauser
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Molecular basis of immunity to rickettsial infection conferred through outer membrane protein B.

Authors:  Yvonne Gar-Yun Chan; Sean Phillip Riley; Emily Chen; Juan José Martinez
Journal:  Infect Immun       Date:  2011-03-28       Impact factor: 3.441

7.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Authors:  Lauriane E Quenee; Nancy A Ciletti; Derek Elli; Timothy M Hermanas; Olaf Schneewind
Journal:  Vaccine       Date:  2011-07-16       Impact factor: 3.641

8.  Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.

Authors:  Tatiana E Erova; Jason A Rosenzweig; Jian Sha; Giovanni Suarez; Johanna C Sierra; Michelle L Kirtley; Christina J van Lier; Maxim V Telepnev; Vladimir L Motin; Ashok K Chopra
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

9.  Chemokine receptor CXCR2 mediates bacterial clearance rather than neutrophil recruitment in a murine model of pneumonic plague.

Authors:  Nicholas A Eisele; Hanni Lee-Lewis; Cynthia Besch-Williford; Charles R Brown; Deborah M Anderson
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

10.  LcrV mutants that abolish Yersinia type III injectisome function.

Authors:  Katherine Given Ligtenberg; Nathan C Miller; Anthony Mitchell; Gregory V Plano; Olaf Schneewind
Journal:  J Bacteriol       Date:  2012-12-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.